{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:16Z","timestamp":1790206216907,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Development of novel antiretrovirals aims at reducing long\u2010term toxicities. Tenofovir disoproxil fumarate (TDF) has been associated with potential nephrotoxicity. The aim of our study was to assess the impact of switching from TDF to tenofovir alafenamide (TAF) on functional nephropathy and lipid parameters in a real\u2010life setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analysed data from 347 HIV\u2010infected patients switching from a TDF\u2010 to a TAF\u2010containing regimen between April and December 2016. Sociodemographic, clinical and laboratory data were collected at TDF\u2010to\u2010TAF switch, and at 3 and 6\u00a0months thereafter. Proteinuria and albuminuria were classified according to Kidney Diseases Improving Global Outcomes (KDIGO) guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At time of switch, moderately and severely increased proteinuria was detected in 32% and 8% of patients, respectively; however, urine dipstick analysis was negative in 84% and 42%, respectively. Moderately and severely increased albuminuria was found in 17% and 3% of patients, respectively. In patients with a urinary protein\u2010to\u2010creatinine ratio (UPCR)\u00a0\u2265\u00a0150\u00a0mg\/g, the mean value declined from 416\u00a0mg\/g at baseline to 272\u00a0mg\/g (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and 242\u00a0mg\/g (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) after 3 and 6\u00a0months, respectively. Patients with an albumin\u2010to\u2010creatinine ratio (UACR)\u00a0\u2265\u00a030\u00a0mg\/g showed no significant decrease of albuminuria. Mean total cholesterol increased from 187 mg\/dL at baseline to 202 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and 208\u00a0mg\/dL (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) at 3 and 6 months, respectively, and mean low\u2010density lipoprotein (LDL) cholesterol increased from 114 mg\/dL at baseline to 124 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and 128\u00a0mg\/dL (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), respectively. As mean high\u2010density lipoprotein (HDL) cholesterol increased from 50 mg\/dL at baseline to 54 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and 57\u00a0mg\/dL (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) at 3 and 6 months, respectively, the LDL:HDL ratio remained stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In an aging HIV\u2010infected cohort, proteinuria and albuminuria were common findings and were underdiagnosed via urine dipstick. Our real\u2010life data suggest that laboratory markers of moderately\/severely increased proteinuria improved after TDF\u2010to\u2010TAF\u2010switch. Lipid profiles were not aggravated. Long\u2010term follow\u2010up is needed to determine the clinical benefit of the TDF\u2010to\u2010TAF switch.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12840","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T15:24:48Z","timestamp":1581953088000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-8903","authenticated-orcid":false,"given":"C","family":"Schwarze\u2010Zander","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Piduhn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Boesecke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schlabe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Stoffel\u2010Wagner","sequence":"additional","affiliation":[{"name":"Institute for Clinical Chemistry and Clinical Pharmacology University Hospital Bonn Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JC","family":"Wasmuth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CP","family":"Strassburg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JK","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Bonn Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Bonn\u2010Cologne Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1766"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898585"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1712-z"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001817"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"e_1_2_5_10_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single\u2010tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV\u20101 (EMERALD): a phase 3, randomised, non\u2010inferiority trial","volume":"5","author":"Orkin C","year":"2018","journal-title":"Lancet HIV"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_2_5_13_1","first-page":"19","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Members KB","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12755"},{"key":"e_1_2_5_15_1","unstructured":"EACS Governing Board.EACS Guidelines Version 10.0 2019."},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000324"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-016-0911-1"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328341f925"},{"key":"e_1_2_5_22_1","first-page":"757","article-title":"Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Mill\u00e1n J","year":"2009","journal-title":"Vasc Health Risk Manag"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T14:17:19Z","timestamp":1692886639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/hiv.12840"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12840","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"2019-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}